The Story Behind the Cover Picture
Couinaud’s corrosion casts of the liver
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:174-175
.
(08 April 2022)
Original Article
Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:176-187
.
(08 April 2022)
This study demonstrated that the machine learning model is a powerful tool to predict early recurrence and provides improvement over other models. This novel model may provide clinicians with useful guidance for postoperative follow-up and treatments.
Xanthophyll β-cryptoxanthin treatment inhibits hepatic steatosis without altering vitamin A status in β-carotene 9',10'-oxygenase knockout mice
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:188-198
.
(08 April 2022)
High intake of provitamin A carotenoid beta-cryptoxanthin is related to a lower risk of nonalcoholic fatty liver disease (NAFLD). The study demonstrated that beta-cryptoxanthin has its own biological functions independent of carotenoid cleavage enzyme and functions as a promising preventative agent against NAFLD development.
Myeloid peroxisome proliferator-activated receptor α deficiency accelerates liver regeneration via IL-6/STAT3 pathway after 2/3 partial hepatectomy in mice
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:199-211
.
(08 April 2022)
Efficient liver regeneration is critical for the treatments of chronic liver diseases, such as donor liver transplantation and tumor resections. This study demonstrates that myeloid PPARα restricts PHx-induced liver regeneration via inhibiting IL-6/STAT3 pathway, thus providing a potential target for improving liver regeneration capacity.
A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:212-226
.
(08 April 2022)
This is the largest single study to assess the prediction of histologic hepatic inflammation by radiomics in NAFLD to date. A radiomics signature based on T2 weighted magnetic resonance imaging non-invasively and accurately identifies severe hepatic inflammation in patients with biopsy-proven NAFLD.
Review Article
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:227-252
.
(08 April 2022)
Therapeutic advances in advanced hepatocellular carcinoma have increased the opportunity for patients with initially unresectable disease to achieve tumor downstaging and undergo surgical resection, a ‘conversion therapy’. We reviewed current evidence for conversion therapy in HCC and developed expert consensus statements to guide clinical practice.
Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:253-266
.
(08 April 2022)
Cholangiocarcinoma is a highly aggressive group of biliary malignancies with limited treatment options and poor overall survival. The advent of next generation sequencing has led to the identification of several new actionable mutations with significant implications for the diagnosis and treatment of this disease.
Editorial from the ACHBPT1
Comment on: “Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial”
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:267-269
.
(08 April 2022)
Comment on: a multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:270-272
.
(08 April 2022)
Editorial
The internet hospital: how to combine with traditional healthcare model
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:273-275
.
(08 April 2022)
The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:276-279
.
(08 April 2022)
Comment on: the tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:280-282
.
(08 April 2022)
Utilization of hepatitis B virus-positive allografts in liver transplantation: a new arrow to the bowstring for expanding the donor pool?
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:283-287
.
(08 April 2022)
Commentary on “The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma”
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:288-291
.
(08 April 2022)
“Digging in the Dirt” faecal microRNAs as dietary biomarkers of host-microbe interactions
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:292-294
.
(08 April 2022)
Pancreatectomy with concomitant portal vein resection in the current neoadjuvant era
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:295-298
.
(08 April 2022)
Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD): distinct fatty liver entities with different clinical outcomes?
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:299-301
.
(08 April 2022)
Positive pancreatic neck margins—a telltale sign of complex biology
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:302-304
.
(08 April 2022)
Age-specific microbiota in altering host inflammatory and metabolic signaling and metabolome based on sex
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:305-307
.
(08 April 2022)
Commentary
Surgery is the means of treatment, but high-quality survival is the ultimate goal
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:308-310
.
(08 April 2022)
Hidden-mortality risk among patients deemed “low-risk” following high-risk operations
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:311-313
.
(08 April 2022)
Comment on “Perihilar cholangiocarcinoma—novel benchmark values for surgical and oncological outcomes from 24 expert centers”
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:314-316
.
(08 April 2022)
Nonalcoholic fatty liver disease in early life and all-cause and cause-specific mortality
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:317-319
.
(08 April 2022)
Drivers and breaks in the cholangiocarcinoma immune microenvironment
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:320-323
.
(08 April 2022)
Loco-regional treatments of unresectable hepatocellular carcinoma: safety first
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:324-326
.
(08 April 2022)
Immunotherapy for hepatocellular carcinoma: a “CRAFITY” approach to patient stratification
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:327-329
.
(08 April 2022)
Viewpoint
Safety and feasibility of laparoscopic pancreatoduodenectomy
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:330-332
.
(08 April 2022)
Letter to the Editor
Metabolic abnormalities play a crucial role in non-obese people suffering from non-alcoholic fatty liver disease (NAFLD)
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:333-334
.
(08 April 2022)
Conversion therapy of stage IVb unresectable gallbladder carcinoma
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:335-337
.
(08 April 2022)
News
Launching of the Sultan Qaboos Comprehensive Cancer Care and Research Center (SQCCCRC) in the Sultanate of Oman to manage HBP type of cancers
HepatoBiliary Surgery and Nutrition
2022;
11
(2)
:338-339
.
(08 April 2022)
Disclosure:
1. The series “Editorial from the ACHBPT” was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition without any sponsorship or funding.
